Tofacitinib for Hospitalized Acute Severe Ulcerative Colitis Management

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 1, 2021

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions
Ulcerative Colitis Acute
Interventions
DRUG

Tofacitinib 10 MG [Xeljanz]

Tofacitinib 10mg PO BID

Trial Locations (1)

L8S 4K1

McMaster University, Hamilton

All Listed Sponsors
collaborator

University of Manitoba

OTHER

collaborator

University of British Columbia

OTHER

collaborator

McGill University

OTHER

collaborator

University of Alberta

OTHER

lead

McMaster University

OTHER